Stock Evaluator: Damora Therapeutics, Inc. (DMRA)

Damora Therapeutics, Inc. DMRA

$22.11 0.51 2.36%
November 16, 2026 11:45:42 AM EST November 10, 2021 Volume: 851,345
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics DMRA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,337.1 $211.8 49%
Shares Out (Mil) 61.8 55.4 52%
Institutional Ownership 99.7% 93.0% 92%
Float (Mil) 41.6 41.5 43%
Beta 1.51 0.99 82%
Avg Daily Volume (000s) 557 553 58%
Price Change
(52-week)
(8.5%) 42.8% 43%
Growth DMRA Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) (43.2%) (10.3%) 9%
EPS (5yr) 4.2% 15.8% 37
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (26.5%) (15.7%) 24%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 4 4 4
Current EPS ($0.470) ($1.885) ($2.185)
Month Ago EPS ($0.473) ($1.895) ($2.173)
# Rev Up 0 2 1
# Rev Down 1 0 0
Three Months Ago EPS ($0.470) ($1.893) ($2.143)
Year/Year Chg 17.5% (98.8%) (98.3%)
Financials DMRA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $41 na
Net Income (TTM) (Mil) ($292) ($44) 4%
EPS (TTM) ($6.640) ($1.500) 6%
Operating Cash Flow (TTM) (Mil) ($59) ($35) 9%
Net Cash Flow (TTM) (Mil) na $-0 na
Long-Term Debt (Q1) (Mil) $1 $4 16%
Enterprise Value (Q1) (Mil) $1,070 $147 42%
Valuation DMRA Industry
Median
Percentile
(All Stocks)
P/B 3.65 2.01 73%
P/E na 17.9 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.0 na
Ratios DMRA Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.9% na
Net Margin na (50.6%) na
ROA (107.4%) (47.4%) 5%
ROE (156.6%) (53.1%) 6%
Liabilities to Assets 6.9% 29.7% 4%
F-Score 2 3 7%

Damora Therapeutics, Inc. did not pass any screens on 11/13/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors